# Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation

> **NCT05456204** · NA · COMPLETED · sponsor: **National Medical Research Center for Cardiology, Ministry of Health of Russian Federation** · enrollment: 120 (actual)

## Conditions studied

- Atrium; Fibrillation
- Atrium; Flutter

## Interventions

- **DRUG:** Pharmacological cardioversion with Refralon

## Key facts

- **NCT ID:** NCT05456204
- **Lead sponsor:** National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05456204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05456204, "Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05456204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*